Tests ubamatamab alone and in combination in platinum-resistant ovarian cancer
Tests an experimental antibody, ubamatamab, alone or with other drugs in ovarian cancer.
Key facts
- Who runs it
- Regeneron Pharmaceuticals
- Where
- Adana, Altındağ, Ankara, Bornova, Gaziantep, Istanbul, Izmir, Sakarya, and Seyhan, TürkiyeSee the 12 sitesAlso in 4 other countries, 44 sites
- Trial code
- Registry title
- Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 397 people, planned
- Started
- 28 May 2025
- Expected to end
- 30 Jun 2028
- Type of study
- Interventional, 10 groups
- Treatments tested
- Ubamatamab
- Bevacizumab
- Cemiplimab
- Fianlimab
- PLD
- Sarilumab
- REGN10597
- Record updated
- 6 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women with advanced platinum-resistant serous or endometrioid ovarian, primary peritoneal or fallopian tube cancer whose disease has progressed on earlier treatment.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Advanced platinum-resistant cancer of the ovary, fallopian tube or peritoneum (serous or endometrioid type, any grade). Clear cell, mucinous and carcinosarcoma types cannot join.
- Earlier treatment
- The cancer must have grown on earlier treatment, shown on scans. At least 1 measurable tumor that was not treated with radiation before.
Main reasons for not taking part
- Major surgery or serious injury within 4 weeks before the first dose
- Past allergic reaction to antibody treatments or doxorubicin
- Another cancer that is growing or needs active treatment
- Untreated or active cancer spread to the brain or its linings
- Uncontrolled infections such as HIV, hepatitis B or hepatitis C, or an immune deficiency
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Participants with histologically or cytologically confirmed diagnosis of advanced serous or endometrioid ovarian (regardless of the grade), primary peritoneal, or fallopian tube cancer (clear cell, mucinous, and carcinosarcoma are excluded)
- Must have progression on prior therapy documented radiographically and must have at least 1 measurable lesion (not previously irradiated) that can be accurately measured by RECIST 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ and bone marrow function, as described in the protocol
- Platinum-Resistant Ovarian Cancer, as described in the protocol
Who cannot take part
- Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study intervention(s)
- Documented allergic or acute hypersensitivity reaction attributed to antibody treatments or doxorubicin hydrochloride or components of study intervention(s)
- Another malignancy that is progressing or requires active treatment, as described in the protocol
- Uncontrolled infections including but not limited to human immunodeficiency virus, hepatitis B or hepatitis C infection, or diagnosis of immunodeficiency
- Untreated or active Central Nervous System (CNS) metastases, or carcinomatous meningitis, as described in the protocol
- Moderate to large or ascites, as described in the protocol
- Bowel obstruction within last 3 months or current need for parenteral nutrition; NOTE: Other protocol-defined inclusion/exclusion criteria apply
Where in Türkiye
Also in 4 other countries, 44 sites
- Baskent UniversityAdana, TürkiyeContact: Clinical Trials AdministratorTaking people
- Hacettepe UniversityAltındağ, TürkiyeContact: Clinical Trials AdministratorTaking people
- Ankara Bilkent City HospitalAnkara, TürkiyeContact: Clinical Trials AdministratorTaking people
- Memorial Ankara HospitalAnkara, TürkiyeContact: Clinical Trials AdministratorTaking people
- Sbu Doctor Abdurrahman Yurtaslan Ankara Onkoloji SuamAnkara, TürkiyeContact: Clinical Trials AdministratorTaking people
- Ege Universitesi Tip Fakultesi HastanesiBornova, TürkiyeContact: Clinical Trials AdministratorTaking people
- Gaziantep Medicalpoint HospitalGaziantep, TürkiyeContact: Clinical Trials AdministratorTaking people
- Cerrahpasa Medical Faculty At Istanbul University CerrahpasaIstanbul, TürkiyeContact: Clinical Trials AdministratorTaking people
- Medipol University HospitalIstanbul, TürkiyeContact: Clinical Trials AdministratorTaking people
- Izmir Ekonomi Universitesi (IEU) Medical Point Izmir Hastanesi (Izmir Economy University Medical Point Izmir Hospital)Izmir, TürkiyeContact: Clinical Trials AdministratorTaking people
- Sakarya University - Education and Research HospitalSakarya, TürkiyeContact: Clinical Trials AdministratorTaking people
- Medicalpark Seyhan HospitalSeyhan, TürkiyeContact: Clinical Trials AdministratorTaking people
About the trial
What the trial wants to find out
This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer.
Read full original descriptionShow less
The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab, REGN10597 and a standard chemotherapy drug, pegylated liposomal doxorubicin [PLD]), referred to as "combination drugs'.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug and its experimental combinations * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) and its combinations
The 10 groups in the trial
- Arm A1Treatment being tested
Treatment: Ubamatamab and Sarilumab
- Arm A2Treatment being tested
Treatment: Ubamatamab and Sarilumab
- Arm BTreatment being tested
Treatment: Ubamatamab, Bevacizumab, and Sarilumab
- Arm CTreatment being tested
Treatment: Ubamatamab, Cemiplimab, Fianlimab, and Sarilumab
- Arm DTreatment being tested
Treatment: Ubamatamab, PLD, and Sarilumab
- Arms E1/E2Treatment being tested
Treatment: Ubamatamab, Sarilumab, and REGN10597
- Arm FaTreatment being tested
Treatment: Ubamatamab
- Arm GaTreatment being tested
Treatment: Ubamatamab and Sarilumab
- Arm FbTreatment being tested
Treatment: Ubamatamab and Bevacizumab
- Arm GbTreatment being tested
Treatment: Ubamatamab, Bevacizumab, and Sarilumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- Multi-Arm Phase 2 Platform Study of Ubamatamab (REGN4018; MUC16×CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer
- Plain-language title
- Tests ubamatamab alone and in combination in platinum-resistant ovarian cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 November 2026